1. EFFICACY OF ORAL HYDROXYCHLOROQUINE IN ONE DOG WITH MUCOCUTANEOUS LUPUS ERYTHEMATOSUS.
- Author
-
TORTORIELLO, R., FERREIRA, D., BOTELHO, C., GOULART DA SILVA, L., MIE EDA, H., and FERNANDES, J.
- Subjects
ANTIMALARIALS ,LUPUS erythematosus ,SKIN diseases in animals ,DOG diseases ,VETERINARY medicine - Abstract
Hydroxychloroquine is an antimalarial drug used in the treatment of human lupus erythematosus according to its immunomodulatory properties without causing systemic immunosuppression. In veterinary medicine, there are only two reports of its use in dermatology. To the authors knowledge, this is the first report of the use of Hydroxychloroquine in the treatment of the mucocutaneous lupus variant in a dog. A 9-year-old, male, 14kg, neutered, crossbreed dog was evaluated with a 2-year history of progressive pruritic erosive skin lesions around the genitals, perianal, anal, and periocular region as well as dyschezia and dysuria. Skin biopsies were consistent with mucocutaneous lupus erythematosus. 1.5mg/kg/day prednisolone was instituted for 30 days with only a partial response. Oral doxycycline was, therefore, added to the previous treatment, at a dosage of 14mg/kg twice daily and 400IU/day of vitamin E. After 30 days, complete remission was obtained, and the steroid treatment was gradually reduced. Hydroxychloroquine was further added, at a dosage of 7mg/kg/day for a period of 60 days. Doxycycline and prednisolone were eventually discontinued. Vitamin E and hydroxychloroquine were maintained daily with no recurrence observed for more than 6 months. Blood count and serum biochemistry were monitored throughout the treatment, revealing no alterations. In conclusion, the use of Hydroxychloroquine has contributed to the maintenance of clinical remission in this patient with mucocutaneous lupus erythematosus, without the need for immunosuppressant therapy. Further controlled studies are needed to confirm the usefulness of this medication in this condition. [ABSTRACT FROM AUTHOR]
- Published
- 2022